These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 18823673)

  • 21. Makes FLASH the difference between the intervention group and the treatment-as-usual group in an evaluation study of a structured education and treatment programme for flash glucose monitoring devices in people with diabetes on intensive insulin therapy: study protocol for a randomised controlled trial.
    Schipfer M; Albrecht C; Ehrmann D; Haak T; Kulzer B; Hermanns N
    Trials; 2018 Feb; 19(1):91. PubMed ID: 29402319
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of insulin initiation on glycaemic variability and glucose profiles in a primary healthcare Type 2 diabetes cohort: analysis of continuous glucose monitoring data from the INITIATION study.
    Manski-Nankervis J; Yates CJ; Blackberry I; Furler J; Ginnivan L; Cohen N; Jenkins A; Vasanthakumar S; Gorelik A; Young D; Best J; O'Neal D
    Diabet Med; 2016 Jun; 33(6):803-11. PubMed ID: 26435033
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c < 7%, without weight gain or hypoglycaemia, over 52 weeks.
    Bergenstal RM; Li Y; Porter TK; Weaver C; Han J
    Diabetes Obes Metab; 2013 Mar; 15(3):264-71. PubMed ID: 23078638
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term tolerance and efficacy of adjunctive exenatide therapy on glycaemic control and bodyweight in type 2 diabetes: a retrospective study from a specialist diabetes outpatient clinic.
    Carrington MJ; Chan YK; Stewart S; Sjouke B; Brazilek R; Cohen N
    Intern Med J; 2014 Apr; 44(4):345-53. PubMed ID: 24877253
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glycaemic control and antidiabetic therapy in patients with diabetes mellitus and chronic kidney disease - cross-sectional data from the German Chronic Kidney Disease (GCKD) cohort.
    Busch M; Nadal J; Schmid M; Paul K; Titze S; Hübner S; Köttgen A; Schultheiss UT; Baid-Agrawal S; Lorenzen J; Schlieper G; Sommerer C; Krane V; Hilge R; Kielstein JT; Kronenberg F; Wanner C; Eckardt KU; Wolf G;
    BMC Nephrol; 2016 Jun; 17(1):59. PubMed ID: 27286816
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The high prevalence of malnutrition in elderly diabetic patients: implications for anti-diabetic drug treatments.
    Vischer UM; Perrenoud L; Genet C; Ardigo S; Registe-Rameau Y; Herrmann FR
    Diabet Med; 2010 Aug; 27(8):918-24. PubMed ID: 20653750
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improving glycaemic control in patients with Type 2 diabetes mellitus without insulin therapy.
    Goudswaard AN; Stolk RP; de Valk HW; Rutten GE
    Diabet Med; 2003 Jul; 20(7):540-4. PubMed ID: 12823234
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
    Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
    Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glycaemic control is a predictor of infection-related hospitalization on haemodialysis patients: Miyazaki Dialysis Cohort study (MID study).
    Toida T; Sato Y; Nakagawa H; Komatsu H; Kikuchi M; Uezono S; Yamada K; Ishihara T; Hisanaga S; Kitamura K; Fujimoto S
    Nephrology (Carlton); 2016 Mar; 21(3):236-40. PubMed ID: 26272229
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An exploratory trial of basal and prandial insulin initiation and titration for type 2 diabetes in primary care with adjunct retrospective continuous glucose monitoring: INITIATION study.
    Blackberry ID; Furler JS; Ginnivan LE; Manski-Nankervis JA; Jenkins A; Cohen N; Best JD; Young D; Liew D; Ward G; O'Neal DN
    Diabetes Res Clin Pract; 2014 Nov; 106(2):247-55. PubMed ID: 25271117
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glycaemic control in patients with type 2 diabetes switching from premixed insulin to long-acting basal insulin analogue plus oral antidiabetic drugs: an observational study.
    Gómez-Peralta F; Carramiñana-Barrera F; Félix-Redondo FJ; Fraile-Gómez J;
    Int J Clin Pract; 2012 Oct; 66(10):959-68. PubMed ID: 22994330
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ProAct study: new features of insulin pumps improve diabetes management and glycemic control in patients after transition of continuous subcutaneous insulin infusion systems.
    Ziegler R; Tubili C; Chico A; Guerci B; Lundberg E; Borchert M; Löffler A; Bloethner S; Weissmann J; Pfützner A
    Diabetes Technol Ther; 2013 Sep; 15(9):738-43. PubMed ID: 23931739
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of insulin lispro protamine suspension versus insulin glargine once daily in basal-bolus therapies with insulin lispro in type 2 diabetes patients: a prospective randomized open-label trial.
    Koivisto V; Cleall S; Pontiroli AE; Giugliano D
    Diabetes Obes Metab; 2011 Dec; 13(12):1149-57. PubMed ID: 21819517
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rates of Deintensification of Blood Pressure and Glycemic Medication Treatment Based on Levels of Control and Life Expectancy in Older Patients With Diabetes Mellitus.
    Sussman JB; Kerr EA; Saini SD; Holleman RG; Klamerus ML; Min LC; Vijan S; Hofer TP
    JAMA Intern Med; 2015 Dec; 175(12):1942-9. PubMed ID: 26502220
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Insulin lispro low mixture twice daily versus basal insulin glargine once daily and prandial insulin lispro once daily in patients with type 2 diabetes requiring insulin intensification: a randomized phase IV trial.
    Tinahones FJ; Gross JL; Onaca A; Cleall S; Rodríguez A
    Diabetes Obes Metab; 2014 Oct; 16(10):963-70. PubMed ID: 24725616
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Switching from Neutral Protamine Hagedorn Insulin to Insulin Glargine 300 U/mL Improves Glycaemic Control and Reduces Hypoglycaemia Risk: Results of a Multicentre, Prospective, Observational Study.
    Wolnik B; Wiza D; Szczepanik T; Syta A; Klupa T
    J Diabetes Res; 2020; 2020():8751348. PubMed ID: 32337298
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
    Dejgaard TF; Frandsen CS; Hansen TS; Almdal T; Urhammer S; Pedersen-Bjergaard U; Jensen T; Jensen AK; Holst JJ; Tarnow L; Knop FK; Madsbad S; Andersen HU
    Lancet Diabetes Endocrinol; 2016 Mar; 4(3):221-232. PubMed ID: 26656289
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Benefit of reduced diabetes medication in elderly with severe multiple comorbidity and low HbA1c. Positive results from a drug withdrawal study among elderly in nursing homes].
    Ostgren CJ; Sjöblom P; Tengblad A; Löfgren UB; Rosenqvist U; Mölstad S
    Lakartidningen; 2009 Jun 10-23; 106(24-25):1649-51. PubMed ID: 19630293
    [No Abstract]   [Full Text] [Related]  

  • 39. New risk and protective factors for severe hypoglycaemia in people with type 1 diabetes.
    Wohland T; Holstein JD; Patzer OM; Mende M; Tiemann T; Koch-Tessarek C; Kovacs P; Holstein A
    Nutr Metab Cardiovasc Dis; 2017 May; 27(5):407-414. PubMed ID: 28216284
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Does hypoglycaemia affect the improvement in QoL after the transition to insulin in people with type 2 diabetes?
    Wieringa TH; de Wit M; Twisk JWR; Snoek FJ
    J Endocrinol Invest; 2018 Feb; 41(2):249-258. PubMed ID: 28803366
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.